标题
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
作者
关键词
-
出版物
OncoImmunology
Volume 5, Issue 12, Pages e1238557
出版商
Informa UK Limited
发表日期
2016-10-14
DOI
10.1080/2162402x.2016.1238557
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
- (2016) Vivek Asati et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
- (2016) Hidenori Mizugaki et al. INVESTIGATIONAL NEW DRUGS
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
- (2015) Eishu Hirata et al. CANCER CELL
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients
- (2015) H. Kakavand et al. CLINICAL CANCER RESEARCH
- Cellular and molecular effects of the mTOR inhibitor everolimus
- (2015) U. Saran et al. CLINICAL SCIENCE
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
- (2015) David R. Minor et al. Pigment Cell & Melanoma Research
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Vemurafenib and ipilimumab: A promising combination? Results of a case series
- (2015) Jessica C. Hassel et al. OncoImmunology
- Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
- (2015) Melanie Sweetlove et al. Frontiers in Oncology
- Foxp3+ T Cells Inhibit Antitumor Immune Memory Modulated by mTOR Inhibition
- (2014) Yanping Wang et al. CANCER RESEARCH
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges
- (2014) Siwen Hu-Lieskovan et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple murine BRafV600Emelanoma cell lines with sensitivity to PLX4032
- (2014) Molly H. Jenkins et al. Pigment Cell & Melanoma Research
- Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- (2014) P. Kvistborg et al. Science Translational Medicine
- PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma
- (2014) Marian M. Deuker et al. Cancer Discovery
- MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
- (2014) L. J. Vella et al. Cancer Immunology Research
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Combining cancer immunotherapy and targeted therapy
- (2013) Antoni Ribas et al. CURRENT OPINION IN IMMUNOLOGY
- Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
- (2013) Victoria Marsh Durban et al. JOURNAL OF CLINICAL INVESTIGATION
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
- (2013) Deborah A. Knight et al. JOURNAL OF CLINICAL INVESTIGATION
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
- (2013) Georgina V. Long et al. Pigment Cell & Melanoma Research
- Synchronous BRAFV600E and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity
- (2013) Christian Blank et al. OncoTargets and Therapy
- mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA
- (2013) M. Diken et al. Cancer Immunology Research
- Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
- (2013) Bishu Sapkota et al. OncoImmunology
- Targeting BRAFV600E in an Inducible Murine Model of Melanoma
- (2012) Anna I. Hooijkaas et al. AMERICAN JOURNAL OF PATHOLOGY
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ T regulatory cell subpopulations
- (2012) C. Scotta et al. HAEMATOLOGICA
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma
- (2012) Anna Hooijkaas et al. OncoImmunology
- BRAF inhibition improves tumor recognition by the immune system
- (2012) Marco Donia et al. OncoImmunology
- Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
- (2011) Y Wang et al. BRITISH JOURNAL OF CANCER
- Combination of targeted therapy and immunotherapy in melanoma
- (2011) Christian U. Blank et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Genetic alterations of PTEN in human melanoma
- (2011) Almass-Houd Aguissa-Touré et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- (2011) Mohammad Atefi et al. PLoS One
- Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy
- (2010) Xuerong Wang et al. CANCER BIOLOGY & THERAPY
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
- (2010) B. Comin-Anduix et al. CLINICAL CANCER RESEARCH
- mTOR regulates memory CD8 T-cell differentiation
- (2009) Koichi Araki et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now